<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "ranitidine tab">
<dose><value>150</value>
<value>300</value>
</dose><route><value>PO</value>
</route><form><value>tab</value>
</form><drugname><value>ranitidine tab</value>
</drugname><strength><value>150 mg</value>
</strength><frequency><value>DAILY</value>
<value>BID</value>
<value>HS</value>
<value>ONCE</value>
</frequency><instruction><value>Administer pre-operatively.</value>
<value>DAY 1 of 21. If oral ranitidine has not been taken by patient as instructed, administer 60 minutes pre-PACLitaxel. May be administered by IV route.</value>
<value>DAY 1 of 21. May be administered by IV route.</value>
<value>DAY 1 of 7. If oral ranitidine has not been taken by patient as instructed, administer 60 minutes pre-PACLitaxel. May be administered by IV route.</value>
<value>DAY 1 of 7. May be administered by IV route.</value>
</instruction><volume></volume><units><value>mg</value>
</units><additionalnotes></additionalnotes><population><value>Adjuvant PACLitaxel/CARBOplatin. Non-Small Cell Lung Cancer</value>
<value>PACLitaxel / CARBOplatin. Advanced / Metastatic Non-Small Cell Lung Cancer</value>
<value>PACLitaxel/CARBOplatin (Weekly) and concurrent RT. Non-Small Cell Lung Cancer.</value>
</population><indicationprn></indicationprn><backgroundinformation></backgroundinformation><prninformation><value>YES</value>
</prninformation><ahsformularystatus><value>Formulary.</value>
</ahsformularystatus><ahfsname><value>Antiulcer Agents and Acid Suppressants, Histamine H2-Antagonists</value>
</ahfsname><highalert></highalert><maximumprndose></maximumprndose><din><value>02242453</value>
</din></drug>